BUSINESS
Max Healthcare Q3FY26 net profit rises 9% to Rs 344 crore
Operating margin slipped to 26.1 percent, down from 27.3 percent a year earlier, the company attributed the margin compression to several factors including discontinuation of high‑value patented chemotherapy drugs for institutional patients after restrictive pricing guidelines from CGHS, pre‑commissioning expenses as new brownfield capacity came online in Mohali, Nanavati Max and Max Smart and GST rate change.
BUSINESS
On World Cancer Day, Tata Trusts CEO flags late diagnosis crisis as India’s cancer cases set to surge 24% by 2030
The Tata Trusts, among India’s oldest philanthropic institutions, have become key players in national cancer care. Their network the largest spans 20 cancer hospitals across states including Assam, Andhra Pradesh, Jharkhand and Maharashtra, with more centres under construction.
BUSINESS
Report finds India targeting the wrong tobacco, 90% of use unregulated, beedis untaxed
Policies target cigarettes even though 90 percent of Indians consume beedis and smokeless tobacco.
BUSINESS
Emcure Pharma net profit jumps 48% in Q3FY26 on strong international business growth
Profit after tax rose to Rs 231 crore in Q3FY26 from Rs 156 crore a year earlier, despite an exceptional expense of Rs 38 crore linked to labour code changes.
BUSINESS
Mankind Pharma Q3 net profit rises 9.5% as BSV boost offsets acute weakness
Revenue from operations increased 11.5% to Rs.3,567 crore.
BUSINESS
Sun Pharma signals willingness to raise debt for acquisitions as cash pile swells to $3.2 bn
'US continues to be an important part of our focus, specifically for the innovative medicines… For emerging markets, we’re looking at tuck‑ins or smaller acquisitions,' Dilip Shanghvi said on M&A strategy. He added that Sun would pursue a deal 'only if we think that it can help us strengthen our long-term strategic capability'
BUSINESS
SPARC wins USFDA priority review voucher tied to Sezaby approval
PRVs are tradable vouchers issued by the USFDA to incentivize development of treatments for rare pediatric conditions, and can be redeemed to secure a priority review for a separate, future drug application—often shaving months off the review clock for high-value assets.
BUSINESS
India-US deal brings relief to nutraceutical exports after customers cut orders and inventories
India's nutraceutical exports, which accounts for almost $1 billion worth of exports, are reeling under severe stress, as US customers are cutting inventories, buying less, delaying launches and even asking for air freight, pushing costs higher.
BUSINESS
Budget 2026: Low spending & unspent funds on public health remains a problem
Jan Swasthya Abhiyan India (JSAI) or the People's Health Movement-India, a national coalition of over 20 networks and over 1,000 NGOs, activists, and health professionals working to secure healthcare as a fundamental right, in a press statement alleged that over the last five years, the Ministry of Health has failed to spend significant portions of its sanctioned outlays.
BUSINESS
Budget 2026 puts India on a research, manufacturing & healthcare‑services fast track
While the Budget offers direct relief for cancer and rare‑disease patients, its deeper thrust lies in building the scientific, regulatory, workforce and infrastructure backbone required for India to lead in next‑generation health innovation.
BUSINESS
Budget 2026: Duty waiver on 17 cancer drugs to cut treatment costs
The move can significantly lower out‑of‑pocket burdens for families, given that India’s health insurance coverage for high‑end oncology biologics and personalised medicines remains limited, say experts
BUSINESS
Budget 2026, 5 regional medical tourism hubs to be built in partnership with private sector
Three new All India Institutes of Ayurveda to be set up and AYUSH pharmacies and drug testing labs to upgraded, says Sitharaman
BUSINESS
In a push for pharma sector, FM Nirmala Sitharaman proposes ‘Biopharma Shakti’ with Rs 10K crore outlay
“The strategy will include a biopharma-focused network with three new National Institutes of Pharmaceutical Education and Research, popularly known as NIPERs, and upgrading seven existing ones,” Sitharaman announced.
BUSINESS
India’s OTC medicines market set to double to Rs.98,000 crore by 2030 says EY‑Parthenon report
The report notes, India’s OTC market is supported by multiple structural tailwinds—including swelling middle‑class affluence, rising out‑of‑pocket healthcare spending and the explosion of digital commerce—that together are “reshaping demand.”
BUSINESS
Indegene Q3 net profit flat as one‑time costs, amortization offset 31% revenue jump
Profit after tax came in at Rs102.6 crore, nearly flat sequentially and down 6.5 percent year‑on‑year, even as revenue rose 30.8 percent YoY to Rs 942.1 crore
BUSINESS
Government sets minimum import price for penicillin, salts; Aurobindo Pharma stock up
The move is being seen as a major win for Aurobindo Pharma, which has invested Rs 3,500-crore to build a massive facility to manufacture penicillin and its salts, which are critical antibiotic raw materials
BUSINESS
Economic Survey calls 'digital addiction' a national health concern, flags erosion of mental wellbeing
India is witnessing a surge in behavioural‑health risks linked to excessive screen time, social‑media overuse and technology‑driven compulsions, especially among adolescents, potentially altering the trajectory of its human capital
BUSINESS
RPG Life Sciences close to acquiring 'major API asset', says MD Ashok Nair
The company is eyeing a revenue of Rs 1,000 crore by 2028 and expects its API plant in Navi Mumbai, which was damaged in a fire in 2025, to resume complete operations by March, Nair tells Moneycontrol
BUSINESS
Piramal Pharma Q3 results: Firm posts net loss of Rs 136 crore on weak CDMO demand
Revenue from operations declined 3% to Rs.2,140 crore, pulled down primarily by a 9 percent fall in the CDMO segment
BUSINESS
Biocon Biologics gets credit rating upgrade by S&P
Shares of parent company Biocon gained 1.34%, to close at Rs.370.15 on BSE on Wednesday, following the ratings announcement.
BUSINESS
Pharma, Medtech industries hail India–EU FTA but seek clarity on regulatory, IP
The agreement, finalised after protracted negotiations, eliminates or drastically reduces tariffs on pharmaceuticals, chemicals and medical devices, while also opening new pathways for Indian medical professionals to work in Europe through formal recognition of their credentials.
BUSINESS
India-EU FTA to boost pharma, chemicals trade, Indian medical professionals' credentials to gain acceptance
The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
BUSINESS
India likely to stand firm on EU data exclusivity, IP demands; may cut duties on pharma, medical devices
India-EU FTA: The EU has been pushing for a six to 10 years’ data exclusivity period, which would prevent India from using an innovator's clinical trial data to approve generic equivalents
BUSINESS
Budget 2026: PMJAY expansion, healthcare infra push beyond tier-1 cities in focus
While public health spending has trended upward, the industry says India must bridge the gap between its current trajectory and the National Health Policy goal of 2.5% of GDP
